Drug Research
Vibalogics Completes Major Milestone in $50M Cuxhaven Facility Expansion with New 500L Manufacturing Line
Vibalogics, a leading virotherapy contract development and manufacturing organization (CDMO) focused on the production of live– viruses and viral vectors, has announced the completion of its expansion project at its GMP facility in Cuxhaven, Germany.
The new building features biosafety...
Press Releases
Thermo Fisher Scientific Launches New GC/GC-MS Instrument Portfolio for Increased Efficiency
Thermo Fisher Scientific Inc., the world leader in serving science, enables analytical testing laboratories across a variety of sectors, including food, environmental, industrial and pharma to now meet their ever-increasing efficiency and productivity needs with a collection of new...
Drug Research
Orbit Discovery and WuXi AppTec sign agreement to access peptide discovery and optimisation technologies
Orbit Discovery (Orbit), a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry.
Orbit will combine...
Press Releases
Vetter’s extraordinary performance sweeps the board at the 2022 CMO Leadership Awards
Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), won the 2022 CMO Leadership Awards in all six core categories – quality, expertise, compatibility, capabilities, reliability and service. Vetter also achieved Champion status in the areas of quality,...
Drug Research
Ray Therapeutics and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership
Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced a manufacturing partnership that will advance Ray Therapeutics’ lead optogenetics gene therapy...
Clinical Trials
IQVIA selected to accelerate clinical development of VYVGART by argenx SE
IQVIA announced an agreement today with argenx SE. The multi-year contract covers a unique collaboration for the development of new indications for VYVGART™ (efgartigimod alfa fcab), an FDA-approved neonatal Fc receptor blocker for the treatment of generalized myasthenia gravis...
Press Releases
Element Partners with Interpretation Expert Genoox to Validate the AVITI System for the RUGD Application
Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, announced a partnership with Genoox, a community-driven genomic data platform, to demonstrate the clinical potential of the AVITI™ system for rare and undiagnosed disease research, using whole-genome...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read